^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ER positive + PGR positive

    i
    Entrez ID:
    2099; 5241
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Apply
    NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer (NCT03789110)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    08/20/2024
    Initiation :
    03/08/2019
    Primary completion :
    09/30/2021
    Completion :
    12/30/2024
    HER-2 • PGR • TMB
    |
    HR positive • HER-2 amplification • HER-2 negative • ER positive + PGR positive • PGR positive
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,) (NCT05283837)
    Phase 3
    Zydus Lifesciences Limited
    Completed
    Last update posted :
    07/18/2024
    Initiation :
    09/26/2022
    Primary completion :
    09/06/2023
    Completion :
    09/06/2023
    HER-2 • ER • PGR
    |
    HER-2 positive • HER-2 overexpression • HER-2 amplification • ER positive + PGR positive • PGR positive
    |
    docetaxel • Perjeta (pertuzumab)
    Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer (NCT05378464)
    Phase 1
    H. Lee Moffitt Cancer Center and Research Insti...
    Recruiting
    Last update posted :
    06/05/2024
    Initiation :
    05/31/2022
    Primary completion :
    07/01/2024
    Completion :
    07/01/2026
    HER-2 • PGR • CD4
    |
    HER-2 positive • HER-2 overexpression • HER-2 amplification • ER positive + PGR positive • PGR positive
    |
    Herceptin (trastuzumab) • Trazimera (trastuzumab-qyyp) • pepinemab (VX15)
    Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib (NCT04614194)
    Phase 2
    University of Texas Southwestern Medical Center
    Recruiting
    Last update posted :
    05/20/2024
    Initiation :
    04/15/2021
    Primary completion :
    04/15/2026
    Completion :
    04/15/2028
    HER-2 • ER • PGR • CD8
    |
    HER-2 negative • ER positive + PGR positive • PGR positive • CD8 positive
    |
    Verzenio (abemaciclib) • letrozole
    Biomarkers to Detect Endocrine Therapy Resistance (NCT06067503)
    Phase 2
    University of Wisconsin, Madison
    Recruiting
    Last update posted :
    05/15/2024
    Initiation :
    04/30/2024
    Primary completion :
    01/01/2026
    Completion :
    01/01/2026
    HER-2 • ER • PGR
    |
    HER-2 negative • ER positive + PGR positive
    A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC) (NCT05675579)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    05/13/2024
    Initiation :
    05/23/2023
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    HER-2 • ER • PGR
    |
    HER-2 negative • ER negative • ER positive + PGR positive • PGR negative
    |
    Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)
    Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort (INSIGHT) (NCT05693766)
    Phase 2
    Sonya Reid
    Recruiting
    Last update posted :
    04/23/2024
    Initiation :
    09/11/2023
    Primary completion :
    08/31/2027
    Completion :
    08/31/2037
    HER-2 • PGR
    |
    HER-2 negative • ER positive + PGR positive
    |
    capecitabine
    A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer (NCT04521764)
    Phase 1
    Mayo Clinic
    Recruiting
    Last update posted :
    04/18/2024
    Initiation :
    09/23/2020
    Primary completion :
    08/15/2027
    Completion :
    08/15/2027
    HER-2 • PD-L1 • ER • PGR • HMGB1
    |
    HER-2 positive • HER-2 negative • ER positive + PGR positive • PGR positive
    Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer (NCT02776917)
    Phase 1
    Barbara Parker, MD
    Completed
    Last update posted :
    04/10/2024
    Initiation :
    08/15/2018
    Primary completion :
    07/13/2021
    Completion :
    02/26/2024
    HER-2 • ER • PGR
    |
    HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • PGR negative
    |
    paclitaxel • zilovertamab (UC-961)
    Seroma of the Mammary Gland (SerMa) (NCT05899387)
    Phase N/A
    University Hospital Augsburg
    Recruiting
    Last update posted :
    04/08/2024
    Initiation :
    04/01/2024
    Primary completion :
    07/01/2024
    Completion :
    07/01/2027
    HER-2 • ER • PGR
    |
    ER positive • ER positive + PGR positive • PGR positive • PGR negative
    Cryoablation vs Lumpectomy in T1 Breast Cancers (COOL-IT) (NCT05505643)
    Phase N/A
    Washington University School of Medicine
    Recruiting
    Last update posted :
    04/08/2024
    Initiation :
    04/03/2024
    Primary completion :
    10/31/2031
    Completion :
    10/31/2031
    HER-2 • PGR
    |
    HER-2 negative • ER positive + PGR positive • PGR positive
    Three Fraction Accelerated Partial Breast Irradiation as the Sole Method of Radiation Therapy for Low-risk Stage 0 and I Breast Carcinoma (NCT03612648)
    Phase N/A
    Washington University School of Medicine
    Active, not recruiting
    Last update posted :
    03/21/2024
    Initiation :
    08/30/2018
    Primary completion :
    03/22/2026
    Completion :
    03/22/2026
    PGR
    |
    ER positive + PGR positive • PGR positive
    Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer (LACOG1018) (NCT03936270)
    Phase 2
    Latin American Cooperative Oncology Group
    Completed
    Last update posted :
    02/20/2024
    Initiation :
    03/05/2020
    Primary completion :
    01/18/2022
    Completion :
    05/02/2023
    ER • PGR
    |
    ER positive + PGR positive
    |
    Ibrance (palbociclib) • letrozole
    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis (NCT02422641)
    Phase 2
    Wake Forest University Health Sciences
    Recruiting
    Last update posted :
    02/12/2024
    Initiation :
    05/01/2015
    Primary completion :
    06/01/2024
    Completion :
    09/01/2024
    HER-2 • ER • PGR
    |
    HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR negative
    |
    methotrexate IV
    Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor (NCT02738866)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Active, not recruiting
    Last update posted :
    02/02/2024
    Initiation :
    10/25/2016
    Primary completion :
    07/01/2024
    Completion :
    12/01/2024
    HER-2 • ER • PGR • PI3K
    |
    ER positive • HER-2 negative • ER positive + PGR positive • ESR1 mutation
    |
    Ibrance (palbociclib) • fulvestrant
    Dose-determining and Dose-confirmatory Study to Investigate the Optimal Dose of Tamoxifen in Breast Cancer Patients According to Genotype Status of TCF20 rs932376 (NCT04961632)
    Phase 1
    National Cancer Centre, Singapore
    Active, not recruiting
    Last update posted :
    02/01/2024
    Initiation :
    12/23/2020
    Primary completion :
    11/01/2025
    Completion :
    11/01/2025
    PGR
    |
    ER positive + PGR positive • PGR positive
    |
    tamoxifen
    Prognostic Indicators for Radiation-induced Breast Fibrosis (NCT05031065)
    Phase N/A
    AHS Cancer Control Alberta
    Recruiting
    Last update posted :
    01/29/2024
    Initiation :
    01/24/2024
    Primary completion :
    07/01/2025
    Completion :
    12/01/2026
    HER-2 • PGR
    |
    HER-2 negative • ER positive + PGR positive • PGR positive
    A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) (NCT04333706)
    Phase 1/2
    University of Southern California
    Recruiting
    Last update posted :
    01/18/2024
    Initiation :
    09/26/2020
    Primary completion :
    11/03/2025
    Completion :
    11/03/2026
    HER-2 • PGR
    |
    HER-2 negative • ER positive + PGR positive
    |
    capecitabine • Kevzara (sarilumab)
    Organoid-based Functional Precision Therapy for Advanced Breast Cancer (ORIENTA) (NCT06102824)
    Phase 2
    Guangdong Provincial People's Hospital
    Recruiting
    Last update posted :
    01/12/2024
    Initiation :
    01/20/2024
    Primary completion :
    06/30/2027
    Completion :
    06/30/2028
    HER-2 • ER • PGR
    |
    HR positive • HER-2 negative • ER positive + PGR positive
    |
    carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • Halaven (eribulin mesylate) • pegylated liposomal doxorubicin • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy) • Ixempra (ixabepilone) • Lipusu (liposomal paclitaxel) • utidelone IV (UTD1)
    Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging (NCT04273555)
    Phase 1/2
    University of Alabama at Birmingham
    Recruiting
    Last update posted :
    12/22/2023
    Initiation :
    03/01/2025
    Primary completion :
    06/30/2028
    Completion :
    06/30/2028
    HER-2 • PGR
    |
    HER-2 positive • ER positive + PGR positive • PGR positive
    Single Fraction High-Gradient Partial Breast Irradiation in Treating Patients With Low-Risk Stage 0-I Breast Cancer (NCT02076074)
    Phase N/A
    Washington University School of Medicine
    Completed
    Last update posted :
    12/05/2023
    Initiation :
    04/02/2014
    Primary completion :
    05/18/2023
    Completion :
    05/18/2023
    PGR
    |
    ER positive + PGR positive • PGR positive
    Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy (REaCT-HER TIME) (NCT04928261)
    Phase 4
    Ottawa Hospital Research Institute
    Recruiting
    Last update posted :
    12/01/2023
    Initiation :
    12/13/2021
    Primary completion :
    09/01/2025
    Completion :
    09/01/2025
    PGR
    |
    HER-2 positive • ER positive + PGR positive • PGR positive
    |
    Herceptin (trastuzumab)
    Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer (NCT04081389)
    Phase 1
    Roswell Park Cancer Institute
    Completed
    Last update posted :
    09/11/2023
    Initiation :
    12/06/2019
    Primary completion :
    05/24/2022
    Completion :
    02/27/2023
    PGR
    |
    ER positive + PGR positive • PGR positive
    |
    paclitaxel • doxorubicin hydrochloride • cyclophosphamide • daunorubicin • Intron A (interferon α-2b) • Ampligen (rintatolimod) • celecoxib oral • cyclophosphamide intravenous
    Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Treated for Newly Diagnosed Breast Cancer (NCT00569543)
    Phase N/A
    University of Nebraska
    Completed
    Last update posted :
    09/01/2023
    Initiation :
    05/11/2005
    Primary completion :
    08/02/2012
    Completion :
    08/02/2012
    ER • PGR
    |
    ER positive + PGR positive • PGR positive
    |
    tamoxifen
    Study of Urine Samples From Women With Newly Diagnosed Breast Cancer Enrolled on Clinical Trial UNMC-08105 (NCT00959244)
    Phase N/A
    University of Nebraska
    Completed
    Last update posted :
    09/01/2023
    Initiation :
    02/02/2009
    Primary completion :
    09/25/2009
    Completion :
    09/25/2009
    ER • PGR
    |
    ER positive + PGR positive • PGR positive
    Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer (Lilly-I3Y-US-I026) (NCT04791384)
    Phase 1/2
    Criterium, Inc.
    Recruiting
    Last update posted :
    07/27/2023
    Initiation :
    04/21/2022
    Primary completion :
    12/01/2024
    Completion :
    01/01/2025
    HER-2 • ER • PGR
    |
    ER positive + PGR positive
    |
    Verzenio (abemaciclib) • Orserdu (elacestrant)
    A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors (NCT03997968)
    Phase 1/2
    Cyteir Therapeutics, Inc.
    Active, not recruiting
    Last update posted :
    07/17/2023
    Initiation :
    10/09/2019
    Primary completion :
    07/30/2024
    Completion :
    12/30/2024
    ER • PGR • MYC • BCL2
    |
    HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • MYC translocation • PGR negative
    |
    gemcitabine • Rituxan (rituximab) • capecitabine • bendamustine • CYT-0851
    Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. (RADIOLA) (NCT05340413)
    Phase 2
    SOLTI Breast Cancer Research Group
    Recruiting
    Last update posted :
    04/18/2023
    Initiation :
    03/25/2022
    Primary completion :
    04/01/2024
    Completion :
    06/01/2024
    HER-2 • PGR • BRCA1 • BRCA2 • HRD • PALB2 • RAD51 • RAD51C • RAD51D
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 amplification • HER-2 negative • PALB2 mutation • ER positive + PGR positive • PGR positive • RAD51C mutation • RAD51D mutation • PGR negative • RAD51 mutation
    |
    Lynparza (olaparib)
    Appetite and Exercise in Breast Cancer Survivors (EARNESt) (NCT04300478)
    Phase N/A
    University of Colorado, Denver
    Completed
    Last update posted :
    03/31/2023
    Initiation :
    02/07/2020
    Primary completion :
    02/02/2022
    Completion :
    02/05/2022
    ER • PGR
    |
    ER positive + PGR positive • PGR positive
    Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer (NCT01846091)
    Phase 1
    Mayo Clinic
    Completed
    Last update posted :
    02/14/2023
    Initiation :
    04/09/2013
    Primary completion :
    09/18/2019
    Completion :
    11/26/2019
    HER-2 • ER • PGR
    |
    HER-2 positive • HER-2 negative • ER positive + PGR positive • PGR positive
    |
    MV-NIS
    To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients. (LUCY) (NCT03286842)
    Phase 3
    AstraZeneca
    Completed
    Last update posted :
    01/16/2023
    Initiation :
    01/17/2018
    Primary completion :
    10/08/2021
    Completion :
    10/08/2021
    HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA
    |
    HER-2 positive • HER-2 negative • ER positive + PGR positive • PGR positive • BRCA mutation • PGR negative
    |
    Lynparza (olaparib)
    RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF (NCT01035099)
    Phase 4
    Weill Medical College of Cornell University
    Completed
    Last update posted :
    12/13/2022
    Initiation :
    11/01/2009
    Primary completion :
    07/23/2019
    Completion :
    09/30/2022
    PGR
    |
    ER positive + PGR positive • PGR positive
    |
    letrozole
    Correlation of Predictive Accuracy of PREDICT Version 2.2 of Indian Women With Operable Breast Cancer (NCT04985253)
    Phase N/A
    Tata Memorial Centre
    Active, not recruiting
    Last update posted :
    10/20/2022
    Initiation :
    11/15/2018
    Primary completion :
    10/18/2021
    Completion :
    12/31/2022
    HER-2 • ER • PGR
    |
    ER positive + PGR positive • PGR positive
    Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer (NCT05525767)
    Phase 4
    Hebei Medical University Fourth Hospital
    Recruiting
    Last update posted :
    09/02/2022
    Initiation :
    03/31/2022
    Primary completion :
    10/31/2024
    Completion :
    12/31/2025
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • ER positive + PGR positive • PGR positive
    |
    Avastin (bevacizumab)
    Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET (NCT04992156)
    Phase N/A
    Fudan University
    Completed
    Last update posted :
    05/19/2022
    Initiation :
    03/15/2017
    Primary completion :
    03/15/2022
    Completion :
    04/15/2022
    HER-2 • ER • PGR
    |
    ER positive + PGR positive • PGR positive
    |
    Ibrance (palbociclib)
    Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China (NCT04334330)
    Phase 2
    Sun Yat-sen University
    Recruiting
    Last update posted :
    05/02/2022
    Initiation :
    12/04/2020
    Primary completion :
    12/30/2023
    Completion :
    12/31/2024
    HER-2 • PGR
    |
    HER-2 positive • ER positive + PGR positive • PGR positive
    |
    Herceptin (trastuzumab) • Ibrance (palbociclib) • lapatinib • Irene (pyrotinib) • fulvestrant
    Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer (NCT03628066)
    Phase 2
    NSABP Foundation Inc
    Completed
    Last update posted :
    04/20/2022
    Initiation :
    10/22/2018
    Primary completion :
    11/30/2020
    Completion :
    01/30/2021
    HER-2
    |
    HR positive • HER-2 negative • ER positive + PGR positive
    |
    Ibrance (palbociclib) • letrozole • goserelin acetate
    Delayed Versus Immediate Use Of Zoledronic Acid For Postmenopausal Patients With Early Breast Cancer Who Are Using Adjuvant Letrozole (NCT05164952)
    Phase 3
    Assiut University
    Recruiting
    Last update posted :
    12/21/2021
    Initiation :
    09/30/2021
    Primary completion :
    08/30/2023
    Completion :
    09/30/2023
    PGR
    |
    ER positive + PGR positive • PGR positive
    |
    letrozole • zoledronic acid
    Sentinel Lymph Node Biopsy in Clinically Node-negative Early Breast Cancer Patients After Neoadjuvant Chemotherapy (NCT03381092)
    Phase N/A
    Peking University
    Recruiting
    Last update posted :
    11/29/2021
    Initiation :
    12/22/2017
    Primary completion :
    06/30/2022
    Completion :
    06/30/2022
    PGR
    |
    HER-2 positive • ER positive + PGR positive • PGR positive
    Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ (IBIS-II DCIS) (NCT00072462)
    Phase 3
    Queen Mary University of London
    Completed
    Last update posted :
    10/06/2021
    Initiation :
    09/01/2003
    Primary completion :
    12/01/2015
    Completion :
    05/31/2021
    PGR
    |
    ER positive + PGR positive • PGR positive
    |
    tamoxifen • anastrozole • Soltamox (tamoxifen citrate)